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Cerebral ischemia is known to induce cell death through hypoxia and oxidative stress 
following reperfusion. However, cell death can spread beyond the ischemic core when toxic 
glutamate levels act on NMDA receptors of surrounding regions. Levels of CXCL12, a 
chemokine primarily released from glia, reportedly elevate following ischemia. Acute 
activation of its receptor, CXCR4, appears to serve a neuroprotective function while 
prolonged activation results in cell death and this cell death was reported to be dependent on 
the combined release of calcium from intracellular stores as well as calcium influx through 
NMDARs. Calcium influx through NMDA receptor channels leads to activation of CaMKII, 
and it has also been shown that intracellular calcium can be sufficient to activate CaMKII. 
Thus, it is of interest to determine if cell death following CXCL12 application is mediated by 
CaMKII; and further, if exposure to CXCL12 primes neurons for glutamate-induced toxicity 
thus increasing cell death. Here, it was confirmed that acute (30 min) delivery of CXCL12 is 
not detrimental, while sustained activation (3 hour) resulted in a significant increase in cell 
death compared to controls. In addition, both acute and sustained CXCL12 exposure induced 
translocation of CaMKII to synapses. Delivery of a strong excitatory stimulus (500 µM glu + 
10 µM gly) following either acute or sustained CXCL12 application appeared to elevate 
susceptibility to glutamate-induced cell death. Interestingly, pre-exposure to CXCL12 also 
induced cell death following delivery of a more physiologically relevant concentration of 
glutamate (100 µM glu + 10 µM gly). Peptide inhibitors that act to block CaM or ATP 
binding to CaMKII both appeared to reduce CXCL12-induced increases in cell death. These 
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results suggest that both acute and sustained CXCR4 activation increase neuron susceptibility 
to excitotoxicity and this priming is at least partially mediated by CaMKII.  
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Cerebral ischemic attack, commonly referred to as stroke, is the leading cause of 
disability, the second leading cause of dementia and the third leading cause of death 
worldwide (Bakhai, 2010). Due to this high prevalence, it is critical to determine the 
underlying mechanisms and causes of stroke-induced cell death. Interestingly, there is strong 
evidence that genetic factors influence the pathogenesis of stroke, but discovery of specific 
mutations has been limited (Hassan and Markus, 2000). Behavioral risk factors and 
preventative measures for stroke are fairly well defined; however, there is still a lack of 
awareness and a lack of emphasis of the behavioral factors which has led to the high stroke 
rates and problems associated with them (Gorelick, 2002). As clinicians continue to try and 
prevent stroke, researchers must continue to study the associated cellular mechanisms in 
order to discover new ways to mitigate brain damage once a stroke has occurred.  
The primary objectives of this introduction are: (A) to summarize the 
pathophysiology of stroke, highlighting excitotoxicity and the inflammatory response; (B) 
discuss different sources of calcium entry and their implications for excitotoxicity; (C) 
highlight the role of CaMKII and its subsequent activity; (D) introduce chemokines; (E) 





Pathophysiology of stroke 
At the gross level, strokes are generally caused by a vascular blockage or a 
hemorrhage which limits blood supply to a given brain area. This infarction translates to a 
loss of oxygen/glucose and results in a complex pathophysiological state; the ischemic core 
suffers from hypoxia, after which cell death is imminent—either by mechanisms of apoptosis 
or by necrosis (Deb et al., 2010). Necrotic cell death leads to release of cellular contents, 
including glutamate, which may be toxic to cells in the surrounding area (referred to as the 
penumbra) that were not directly affected by the ischemic event. In addition to excitotoxicity, 
the penumbra is subjected to potentially deleterious effects arising from ionic imbalances and 
activation of inflammatory pathways. However, cell death in the penumbra is considered 
secondary to the stroke itself and may be preventable through early interventions. 
Excitotoxicity 
The term “excitotoxicity” was first coined by Olney (1969), following the observation 
that over-excitation of neurons with glutamate results in their death. Since then, many of the 
underlying mechanisms have been elucidated. These include rises of intracellular calcium 
mediated by calcium permeable ion channels; specifically, NMDA receptors (Tymianski, 
Charlton & Carlen, 1993), and to a lesser extent L-type voltage gated calcium channels (L-
VGCCs; Brewer et al., 2007; Stanika et al., 2012).  
In normal excitatory conditions, increased intracellular calcium activates a multitude 
of pathways, notably the calcium/calmodulin (CaM)-dependent kinase II (CaMKII) signaling 
cascade which mediates learning and memory through mechanisms of LTP and LTD 
(Lisman et al., 2002). In hyper-excitatory conditions, such as those following stroke, an 
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increase of intracellular calcium activates CaMKII, which is believed to participate in a 
cascade that can increase damage resulting from excitotoxic events (see Coultrap et al., 
2011). For instance, CaMKII may increase and prolong calcium overload by increasing 
cation conductance of AMPARs (Liu & Zukin, 2007), L-VGCCs (Grueter et al., 2006), and 
acid sensing ion channels (Gao et al., 2005); thus, enhancing the overexcited state and 
potentially exacerbating cell death. However, some downstream targets of CaMKII may 
promote cell survival including phosphorylation and inhibition of nitric oxide synthase 
(Osuka et al., 2002), insertion of inhibitory GABAA receptors (Mardsen et al., 2010), and 
activation of Ras/ERK (Illario et al., 2003).  These opposing actions of CaMKII may be 
triggered by different sources of calcium, and raise the possibility that the most effective 
treatment for stroke might be one that inhibits detrimental effects but enhances the 
neuroprotective effects of CaMKII. 
NMDA receptors have been targets of intervention following stroke by inhibitory 
drugs which block downstream pathway activation, however these interventions have been 
largely unsuccessful when tested in humans (Villman & Becker, 2007; Lau & Tymianski, 
2010). Alternatively, inhibition of CaMKII has been shown to enhance cell survival 
following high glutamate exposure if inhibition follows the stimulus and is short lasting 
(Vest et al., 2010); however, CaMKII inhibition results in cell death if inhibition is greater 
than four hours in duration (Ashpole et al., 2012).  
 Inflammatory response 
The inflammatory response pathway induces release of signaling molecules, termed 
chemokines, in areas that are affected by traumatic events such as stroke or blunt force 
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trauma (Smith, 2013). Acute exposure to chemokines is intended to lead pro-inflammatory 
response cells to the area of trauma, but sustained chemokine exposure to nearby neurons 
results in cell death (Shepherd et al., 2012). Specifically, prolonged CXCR4 activation by 
CXCL12 (formerly referred to as SDF-1alpha) has been shown to result in increases of cell 
death in culture. CXCL12 binds to its receptor CXCR4, which is a G-protein coupled protein. 
Upon binding of a ligand, CXCR4 triggers release of calcium from intracellular stores and 
the possible activation of CaMKII (Shakiryanova et al., 2011; McCord et al., 2013). Thus, 
CXCR4 activation may activate CaMKII following ischemia.   
 
Calcium sources 
Calcium influx into the cytosol is a highly regulated process that allows for calcium 
to act as a reliable signaling molecule responsible for the activation of a multitude of 
pathways. Extracellular concentrations of calcium are on the order of 10
-3
 mM while 
intracellular concentrations 10
-7
 mM are several orders of magnitudes lower. While there are 
many possible modes for intracellular Ca
2+
 to become elevated, three particular mechanisms 
are of interest to excitotoxicity and chemokine-activity: 1) influx through the NMDA-type 
glutamate receptor; 2) influx through L-type voltage dependent calcium channels; and 3) 
release from intracellular stores.  
NMDA receptors 
The primary excitatory neurotransmitter in the mammalian central nervous system is 
the amino acid, L-glutamate. Glutamate acts on both ionotropic glutamate receptors (iGluRs) 
and metabotropic glutamate receptors.  Three distinct types of iGluRs are present in the CNS: 
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1) N-methyl-D-aspartate (NMDA) receptors; 2) α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors; and 3) kainate receptors. Upon activation by 




 permeable and kinetically characterized 
by their rapid activation and desensitization (1-10 ms). NMDA receptors require glutamate, 
glycine, and a partially depolarized environment to dislodge a Mg
2+
 ion block to be activated, 
and are thus thought of as “coincidence detectors” (Yuste et al., 1999). NMDAR activation 
and desensitization occur on a 10-100 ms timeline and while active, NMDARs are permeable 
to cations, most notably Ca
2+
. Activation kinetics and calcium permeability are dependent on 
the subunit composition of any given NMDAR. In cortex, NMDARs are heterotetramers 
described as a dimer-of-dimers, requiring two dimers each with an obligatory glycine-
activated GluN1 subunit and a glutamate-activated GluN2 (A-D) subunit.  
Influx of Ca
2+
 through NMDARs results in the activation of calcium dependent 
signaling pathways, some contribute to excitotoxicity and others contribute to 
neuroprotective mechanisms (Arundine et al., 2003). This contribution is currently believed 
to depend on the subunit composition of NMDARs—evidence currently indicates that 
GluN2B-containing NMDARs contribute pro-death signals while GluN2A-containing 
NMDARs contribute pro-survival signals (Mony et al., 2009). It appears this is a least 
partially due to the specific characteristics of the GluN2B C-tail. The long 2B-tail allows for 
significant interactions with CaMKII (Bayer et al., 2006), which may situate CaMKII in a 
way that over-activates the kinase and sets many cell-death pathways in motion (Martel et al. 
2010). Currently, GluN2B-containing NMDARs are the target of allosteric modulators for 
potential therapeutic benefits related to excitotoxicity (Mony et al.).  
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As mentioned previously, drugs targeting NMDA receptors have been utilized as an 
intervention following stroke by, however these interventions have been largely unsuccessful 
when tested in humans (Villman & Becker, 2007; Lau & Tymianski, 2010). For example, 
derivatives from known negative allosteric modulators (i.e., ifenprodil), have failed to 
produce decreases in stroke related cell death in clinical trials (Tahirovic et al., 2008). This 
lack of effect may in part be due to the fact that additional routes of calcium influx beyond 
NMDARs continue to activate pro-death calcium-dependent pathways. The next section 
examines one of these alternative routes of Ca
2+
 influx. 
Voltage gated calcium channels 
L-type VGCC’s are calcium permeable channels that are voltage dependent. Their 
activation is known to affect secretion of neurohormones and neurotransmitters, gene 
expression, mRNA stability, synaptic efficacy, and the activity of other ion channels 
(Lipscombe et al., 2004). More importantly to the current study, they have also been 
implicated in ischemic-induced neuronal injury and neuronal survival (Stanika et al., 2012).  
L-VGCCs activate at voltages that typically result in depolarization of the cell 
(Lipscombe et al., 2012). Generally, this occurs following the large cation influx that is 
mediated by NMDARs, however in ischemic conditions, it is possible that contributions from 
AMPARs and acid sensing ion channels are enough to induce VGCC activation. This 
calcium influx may then subsequently activate CaMKII (Rose et al., 2009). This will be 




Intracellular calcium stores 
 In addition to external-to-internal calcium conductance to increase cytoplasmic 
calcium, neurons can release calcium from their own intracellular stores in the endoplasmic 
reticulum (ER). One mechanism that induces the release of intracellular calcium is the 
activation of inositol triphosphate (IP3) receptors. In chemokine signaling, the activation of 
chemokine receptors induces activity that creates IP3, which then serves to activate IP3 
receptors in the ER (Murdoch and Finn, 2000). Importantly, release of intracellular calcium 
has been demonstrated to result in activity of CaMKII in some conditions (McCord et al., 
2013).  
 
Calcium dependent pathways 
CaMKII 
 CaMKII is a dodecameric serine/threonine protein kinase that is ubiquitously 
expressed throughout the brain comprising ~2% of total protein (Miller & Kennedy, 1995). 
Both the α and β form of CaMKII are implicated in regulating many learning and memory 
processes (see Coultrap et al., 2012), although through different mechanisms (Okamoto et al., 
2008). CaMKII activity is triggered by calcium-bound-calmodulin (Ca
2+
/CaM) following the 
elevation of intracellular calcium. Ca
2+
/CaM binding to CaMKII induces a conformational 
change exposing multiple phosphorylation and substrate binding sites; this conformational 
change also allows the subunit to bind ATP and phosphorylate substrates (Figure 1; Meyer et 
al., 1992). CaMKII can autophosphorylate at multiple sites in its regulatory domain, 
including threonine 286 (T286); T286 phosphorylation occurs between the autoinhibitory and 
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substrate binding sites, which keeps the subunit locked open and active if intracellular Ca
2+
 
levels drop and CaM dissociates (termed autonomy) (Colbran et al., 1989; Bayer et al., 
2001). CaMKII translocation to synapses is enhanced following T286 phosphorylation 
(Strack et al., 1997) however, it is not necessary (Shen & Meyer, 1999). Synaptic 
translocation of CaMKII allows it to binds and/or phosphorylate numerous substrates that are 
involved in learning and memory, as well as ischemia-induced cell death (Coultrap et al, 
2011; 2012). Once Ca
2+/
CaM has dissociated from the CaM binding site, T305/306 “burst” 
autophosphorylation can occur; inhibiting further Ca
2+/
CaM binding and rendering the kinase 
inactive (Colbran & Solderling, 1990). In this state, CaMKII can no longer phosphorylate 









Figure 1. Cartoon depiction of CaMKII. A. Ribbon structure of CaMKII dodecamer. The 
entire enzyme is around 120Å wide and 60Å thick (Ribbon animation; Rosenberg et al., 
2005). B. Bubble structure of inactivated and activated kinase demonstrating the 
conformational change induced by Ca
2+
/CaM exposing the phosphorylation sites. Each 
CaMKII subunit consists of three domains: the C-terminal association domain, which binds 
to neighboring subunits; the regulatory domain, which includes the majority of the known 
phosphorylation sites, as well as the CaM binding autoinhibitory domain; and the ATP 
binding N-terminal catalytic domain (Rosenberg et al., 2005; Bubble structure from Rellos et 
al., 2010).  
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Due to high glutamate levels, CaMKII translocation to the synapse is observed 
following excitotoxic insults (Vest et al., 2010). As noted earlier, several substrates are 
targeted by CaMKII following excitotoxic insults, some of which are thought to induce cell 
death and while others promote survival (Coultrap et al, 2011). One of the primary targets of 
CaMKII following ischemia is the GluN2B subunit of the NMDA receptor which is thought 
to be cell-death related; this is due in part to the fact that when CaMKII is bound to GluN2B, 
it will remain in a locked, open state and may phosphorylate cell-death inducing substrates 
(Bayer et al., 2001; 2006; Barria et al., 2005). Additional death inducing targets include ion 
channels such as AMPARs (Liu & Zukin, 2007), L-VGCCs (Grueter et al., 2006), and acid 
sensing ion channels (Gao et al., 2005); targeting of these channels are thought to enhance 
the overexcited state through influx of cations and exacerbate cell death. 
 Pro-survival targets include: phosphorylation and inhibition of nitric oxide synthase, 
which would otherwise induce oxidative stress and eventually induces apoptosis (Osuka et 
al., 2002); insertion of inhibitory GABAA  receptors, which allows for the influx of anions to 
counteract the influx of cations (Mardsen et al., 2010); activation of Ras/ERK which serves 
to counteract apoptosis related phosphorylation (Illario et al., 2003, El Gaamouch et al., 
2012); and activation of cAMP response element-binding (CREB), which binds to CRE and 
increases gene transcription of pro-survival genes (Wheeler et al., 2008).  
Due to the number of cell-death causing targets, inhibiting CaMKII activity has been 
studied as a means to reduce cell death following stroke (Vest et al. 2010; Ashpole et al., 
2011). In several studies, inhibition of CaMKII activity following stroke with potent 
inhibitory peptides has resulted in the survival of neurons in culture, as well as decreased 
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infarct size in rodent models of stroke (Coultrap et al., 2011; Ashpole & Hudmon, 2011).  
However, prolonged inhibition of CaMKII lasting >6 hours appears to be detrimental to 
neurons (Ashpole & Hudmon, 2011). One goal of the current study is further investigation 
into CaMKII inhibition following chemokine and glutamate induced CaMKII activity. 
 
Inflammation Response 
 In addition to excitotoxic pathways, inflammatory response pathways become 
activated following ischemia. Leukocyte influx and activation of microglia are initial phases 
of the inflammatory response (Becker, 1998). In order for leukocytes and microglia to 
migrate to the affected area following stroke, they chemotax along high concentration 
gradients of chemotactic cytokines, or chemokines (Gouwy et al., 2004). 
Chemokines 
Chemokines are signaling proteins released from neurons and glia that induce 
chemotaxis from nearby inflammatory response cells. However, they also directly couple 
neurons through binding of metabotropic chemokine receptors (Meucci et al., 1998). Four 
distinct types of chemokines exist: C, CC, CXC, and CX3C, named for the characteristic 
cysteine residue at the N-terminal region of the chemokine (Fernandez et al., 2002). Here, I 
will focus on the CXC-type because of their implication in the death of neurons as a result of 
stroke.  
 Following stroke, chemokine expression (CXCL12, specifically) is upregulated in 
the penumbra both by glia and neurons (Hill et al., 2004). This upregulation of CXCL12 is 
likely intended to bind to CXC-receptors (CXCRs) on microglia as a chemotactic signal to 
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inflammatory response cells, however CXCRs are also present in neurons (Meucci et al., 
1998). Activation of chemokine receptors by chemokine ligands is important during 
development for helping to control axonal migration; additionally, CXCL12 may act as a 
neuromodulator in mature cells (Guyon and Nahon, 2007).  
Chemokine receptors 
In neurons, CXC-receptors are G-protein coupled receptors with 7 transmembrane 
domains (Fernandex et al., 2002). The specific receptor for CXCL12 is CXCR4. CXCR4 is 
predominately distributed throughout the somatodendritic region of hippocampal neurons 
(Shepherd et al., 2012). Upon binding of a ligand, the G-protein creates IP3 which 
translocates and triggers the release of calcium from intracellular stores (Murdoch and Finn, 
2004). This calcium release can then activate CaM and the associated calcium dependent 
processes previously discussed.  
In pathological states, CXCL12 may be both protective and detrimental following 
activity that mimics stroke (Shepherd et al., 2012). Specifically, CXCR4 activation by 
CXCL12 has been shown to increases cell death following prolonged activation (Figure 2). 
In addition, it has been shown that down-regulation of CXCR4 with the anti-inflammatory 
drug dexamethasone is neuroprotective and reduces infarct size in rodent models of 
hypoxia/ischemia (Felszeghy et al., 2004). Release of intracellular calcium has been 
demonstrated to activate CaMKII following oxidative stress (McCord et al., 2013) thus 






Figure 2.  Sustained CXCR4 signaling. CXCL12 is released from cells in the ischemic 
penumbra, this then binds to CXCR4, which is present in hippocampal neurons; prolonged 
CXCR4 activation then induces rises in intracellular calcium that combine with 
NMDA/VGCC mediated calcium rises to activate CaM. Subsequently, CaM activates 
Calcineurin (a protein phosphatase that dephosphorylates substrates) which activates voltage 
gated potassium channels subsequently allowing excessive potassium efflux. Following this, 
cells become stressed, and the apoptosis pathway is triggered. Not shown is the activation of 





The proposed model of CXCL12 induced cell death is as follows (from Shepherd et 
al., 2012):  
1) CXCL12 is released from cells in the ischemic penumbra  
2) CXCR4 receptors become activated;  
3) Prolonged CXCR4 activation (3 hour) induces rises in intracellular calcium that 
combine with NMDA/VGCC mediated calcium rises to activate CaM.  
4) CaM activates Calcineurin (a protein phosphatase that dephosphorylates 
substrates) which activates voltage gated potassium channels and subsequently 
allows excessive potassium efflux;  
5) Cells undergo mitochondrial dysfunction and the apoptosis pathway is activated.  
 
In contrast to prolonged CXCL12 exposure, acute CXCL12 exposure (30 min) 
appears to induce a calcium spike which is mitigated by acute outward potassium 
conductance through voltage gated potassium channels. The present study examined if 
CXCR4 signaling enhances CaMKII activity that may mediate cell death.  
Concentrations of 500 µM glutamate are commonly used as a reliable excitotoxic 
stimulus when studying glutamate’s intracellular effects, while concentrations of 100 µM are 
used to produce a moderate, excitatory stimulus (Vest et al., 2010; Shen & Meyer, 1999). 
Here, I examined if these two different concentrations of glutamate (500 µM and 100 µM) 
interact with the effects of CXCR4 activation (acute and sustained), to produce increased cell 
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death or attenuated cell death. The data collected suggests that different calcium sources act 
synergistically to increase a detrimental calcium signal.  
 
Specific Aims  
 This thesis research utilized cultured hippocampal neurons to investigate the role of 
CaMKII in CXCL12-dependent cell death. In order to determine the role of CaMKII in the 
cellular response to CXCL12, immunocytochemistry was used to determine the localization 
of CaMKII following CXCL12 exposure and subsequent glutamate + glycine exposure. 
Specific aims were as follows: 
1. Establish cell death ratios following acute and sustained CXCL12 exposure 
and a subsequent glutamate + glycine challenge. 
2. Establish CaMKII localization patterns following CXCL12 and a subsequent 
glutamate + glycine challenge. 
3. Inhibit CaMKII activity during CXCL12 pre-exposure and examine if rates of 
cell death change following a subsequent glutamate + glycine challenge. 
4. Inhibit CaMKII activity during CXCL12 pre-exposure and examine if 











All experiments involving the use of rats and the procedures were approved by the 
Western Washington University Institutional Animal Care and Use Committee and were in 
strict accordance with the Guide for the Care and Use of Laboratory Animals described by 
the National Institutes of Health.  
 
Primary culture of rat hippocampal neurons 
Hippocampal neurons from rat embryos were isolated and cultured as described by 
Kaech and Banker (2006). Hippocampi from Sprague-Dawley rat embryos of either sex were 
removed at embryonic day 18 and incubated in Hank’s Buffered Saline Solution (HBSS; 
Gibco) with trypsin (1 mg/ml; Gibco) for 15 min at 37°C. Hippocampi were then washed six 
times with HBSS, followed by trituration to dissociate cells. Cells were then counted and 
plated onto poly-D-lysine-coated (MW > 100,000; Sigma) glass coverslips at a density of 
150,000 cells per 60 mm dish in Neurobasal medium containing (Gibco) B27 (Gibco), 0.6 
mM glutamine and penicillin/streptomycin. The cells were incubated in a 5% CO2 incubator 
at 37°C for 2–4 h, after which the coverslips were transferred to a previously prepared dish 
containing a glial feeder layer (as described by Kaech and Banker) in 
Neurobasal/B27/glutamine media and maintained at 37°C in a 5% CO2 incubator. One-third 
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of the medium was exchanged weekly and APV was added twice weekly. All experiments 
were performed on neurons that were cultured for 14–16 days in vitro (DIV).  
 
Experimental treatment 
Coverslips were removed from their glial dishes and briefly washed in extracellular 
solution (ECS; in mM: 168 NaCl, 2.4 KCl, 10 HEPES, 10 D-glucose, 1.3 CaCl2, 1.3 MgCl2, 
pH 7.3) and placed face up. 100µL of 100nM CXCL12 (Peprotech; and produced by Dr. 
John Antos, WWU Chemistry Department) in ECS was applied to each coverslip for either 
30 minutes (acute treatment) or 3 hours (sustained treatment). Subsequently, 500µM or 
100µM glutamate + 10 µM glycine in ECS was applied for 1 min. The glutamate + glycine 
solution was then removed and replaced with ECS and incubated for an additional 15 min or 
60 min. Cells were treated with a cell death assay and immunocytochemistry (ICC) at the end 
of their prescribed incubation time.  
To assess the role of CaMKII, the CaMKII/CaM inhibitor peptide SC3037 (Santa 
Cruz Biotechnology; Sequence: LKKFNARRKLKGAILTTMLA ) and the CaMKII inhibitor 
SC3039 (Santa Cruz Biotechnology; Sequence: MHRQEAVDCLKKFNARRKLKGA) were 
used (final concentration: 1 µM) to inhibit the activity of CaMKII during the CXCL12 
incubation and glutamate + glycine stimulations. Peptides inhibitors were co-administered 
with CXCL12 and remained until washout of glutamate + glycine. See Appendix D for 
model depicting action of SC3037 and SC3039. 
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For controls, neurons were incubated in ECS for the corresponding duration of the 
experiment and were then treated with the same cell death assay followed by the ICC 
protocol.   
 
Cell death assay and immunocytochemistry 
Following experimental treatment, neurons were incubated for 15 min at room 
temperature (RT) in fixable viability dye eFluor-660 (eBioscience) as a marker of 
compromised cells destined to dye, immediately followed by 12 min RT incubation in 37°C 
4% paraformaldehyde to permanently fix cells. Cells were then permeablized in 0.25% 
Triton X, and blocked in 10% bovine serum albumin for 30 min at 37°C. Primary antibodies 
mouse monoclonal anti-CaMKII IgG1 (1:1000, Abcam) and mouse monoclonal anti-PSD95 
IgG2a (1:1000, Abcam), were applied at RT overnight on a shaker. Secondary antibodies 
Alexa Flour 568-conjugated anti-mouse IgG1 (1:800) and Alexa Flour 488-conjugated anti-
mouse IgG2a (1:400) were applied for 45 min at 37°C. Cells were mounted on glass slides in 
DAPI mounting medium (Southern Biotechnology) and sealed with nail polish. Slides were 
imaged using an Olympus IX-80 inverted microscope with epifluorescence. All images were 
collected with a CCD camera (Hamamatsu) using Metamorph basic software (Molecular 
Devices, Inc.). See Appendix A and B for sample images. 
 
Data analysis 
To assess cell death, all groups were imaged with a 20X objective and three channels 
were collected; DIC, CY5 (to image the cell death marker), and DAPI (to image nucleus-
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bound DAPI). Each image yielded 10-60 neurons; each coverslip was imaged in 5-10 
different locations. To analyze each image, DAPI stained cells were counted to get the total 
cell count and CY5 stained cells were counted to get the dead cell count.  Cell death ratios 
were calculated.             
   
    
  
To assess CaMKII localization, all images were collected with a 40X oil objective 
and three channels were collected; DIC, FITC (to image PSD95), Texas Red (to image 
CaMKII). Five to ten neuron images per coverslip were collected. To quantify CaMKII co-
localization with PSD95, the ImageJ (NIH) plug-in JaCOP was used to measure and compare 
the degree of overlap between CaMKII puncta and PSD95 puncta. 
Data were analyzed using SPSS (IBM) with a one-way ANOVA to compare means 
within each group. Dunnett’s post-hoc test was used to compare means in each cell death 
condition to the CXCR4 condition. REGW-Q post-hoc test was used to compare all CaMKII 





Chapter 3: Results 
 
 
Glutamate + glycine results in cell death 
Exposure to glutamate + glycine significantly increased cell death F (4, 62) = 14.81, p 
< .0001. REGW-Q post-hoc was used to compare all means and keep a family-wise alpha of 
.05. REGW-Q post-hoc comparisons revealed that ECS, and the two 100µM were not 
significantly greater than ECS.  However, 15 min post 500µM glutamate + glycine showed 
significant increases in cell death, while 60 mins post 500µM glutamate + glycine showed 




Figure 3. Glutamate + Glycine viability dye ratios. * indicates significant comparison to 











































CXCL12 enhances glutamate induced cell death 
A one-way ANOVA revealed a main effect of acute CXCL12 exposure and glutamate 
+ glycine on cell death, F (5, 63) = 22.04, p < .0001. Dunnett’s post-hoc test comparing 
experimental treatments to ECS control revealed that acute CXCL12 exposure had no effect 
on cell death (p > .05). However, cell death levels following 100µM and 500µM glutamate + 
glycine visualized 15 mins and 60 mins post-treatment were significantly higher than 
controls (p < .05) (Figure 3a).  
A one-way ANOVA revealed a main effect of sustained CXCL12 exposure and 
glutamate + glycine on cell death, F (5, 75) = 103.608, p < .001. Dunnett’s post-hoc test 
comparing experimental treatments to ECS control revealed that acute CXCL12 exposure 
had a significant increase on cell death (p < .05). Interestingly, cell death levels following 
100µM and 500µM glutamate + glycine visualized 15 min- and 60 mins post-treatment were 




Figure 4. CXCL12 viability dye ratios.  * indicates significant Dunnett’s post-hoc 



















































































SC3037 attenuates glutamate induced cell death following CXCL12 exposure 
A one-way ANOVA revealed a main effect of acute CXCL12 exposure combined 
with the CaMKII inhibitor SC3037 and glutamate + glycine on cell death, F(5, 51) = 4.256, p 
= .002. Dunnett’s post-hoc test comparing all treatments to CXCL12 + SC3037 revealed that 
acute exposure of the chemokine with inhibitor had no effect on cell death compared to ECS 
(p > .05). Additionally, cell death levels following 100µM and 500µM glutamate + glycine 
visualized 15 min-post treatment and 100µM 60 mins post-treatment were not higher than 
ECS controls. Interestingly, 500µM glutamate + glycine exposure visualized 60 mins 
following acute CXCL12 + SC3037 resulted in significantly higher cell death (p < .05) 
(Figure 4a).  
A one-way ANOVA revealed a main effect of sustained CXCL12 + SC3037 exposure 
and glutamate + glycine on cell death, F (5, 44) = 4.523, p < .003. Dunnett’s post-hoc test 
comparing all treatments to CXCL12 + SC3037 revealed that sustained CXCL12 + SC3037 
exposure had a significant increase on cell death compared to ECS controls (p < .05). 
However, cell death levels following 100µM and 500µM glutamate + glycine visualized 15 
min-post treatment and at 60 mins post-treatment were not significantly different than 






    
Figure 5.  CXCL12 + SC3037 viability dye ratios. * indicates significant Dunnett’s post-hoc 































































































SC3039 interferes with CXCL12 induced cell death   
A one-way ANOVA revealed a main effect of acute CXCL12 exposure combined 
with the CaMKII inhibitor SC3039 and glutamate + glycine on cell death F (5, 84) = 4.284, p 
= .002. Dunnett’s post-hoc test comparing all treatments to CXCL12 + SC3039 revealed that 
acute exposure had no effect on cell death compared to ECS (p > .05). Additionally, cell 
death levels following 100µM and 500µM glutamate + glycine visualized 15 min-post 
treatment and 100µM 60 mins post-treatment were not higher than ECS controls. 500µM 
glutamate + glycine exposure visualized 60 mins following acute CXCL12 + SC3039 
resulted in significantly higher cell death (p < .05) (Figure 5a).  
A one-way ANOVA revealed a main effect of sustained CXCL12 + SC3037 exposure 
and glutamate + glycine on cell death F (5, 84) = 7.906, p < .0001. Dunnett’s post-hoc test 
comparing all treatments to CXCL12 + SC3039 revealed that sustained CXCL12 + SC3039 
exposure had a significant effect on cell death compared to control (p < .05). Additionally, 
cell death levels following 100µM and 500µM glutamate + glycine visualized 15 min-post 
treatment and at 60 mins in the 100µM post-treatment were not significantly different than 
CXCR4 + SC3039 (p > .05). However, 500µM glutamate + glycine exposure visualized 60 
mins following acute CXCL12 + SC3039 resulted in significantly higher cell death (p < .05) 




Figure 6. CXCL12 + SC3039 cell death ratios. * indicates significant Dunnett’s post-hoc 
































































































CaMKII synaptic translocation is induced by CXCL12 and glutamate  
A one-way ANOVA revealed a main effect of acute CXCL12 exposure and glutamate 
+ glycine on synaptic CaMKII translocation, F (5, 43) = 10.368, p < .001. REGW-Q post-hoc 
was used to compare all means and keep a family-wise alpha of .05. REGW-Q revealed that 
all exposure conditions showed significantly greater synaptic CaMKII than ECS as measured 
by degree of colocalization with the synaptic marker PSD (Figure 7a).  
A one-way ANOVA revealed a main effect of sustained CXCL12 exposure and 
glutamate + glycine on synaptic CaMKII translocation, F (5, 39) = 4.039, p < .001. REGW-Q 
revealed that all exposure conditions showed significantly greater synaptic CaMKII than 




Figure 7. CXCL12 PSD/CaMKIIsynaptic ratios. * indicates significant Dunnett’s post-hoc 
comparison with ECS as control; p < .05 for of all comparisons with ECS as control; p < .05 
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SC3037 inhibits CaMKII synaptic translocation 
A one-way ANOVA revealed no main effect of acute CXCL12 exposure combined 
with the CaMKII inhibitor SC3037 and glutamate + glycine on CaMKII synaptic 
translocation F (5, 74) = 1.211, p = 1.211 (Figure 8a).  
A one-way ANOVA revealed no main effect of sustained CXCL12 + SC3037 
exposure and glutamate + glycine on synaptic CaMKII translocation F (5, 64) = 1.685, p = 
































































































SC3039 allows CaMKII synaptic translocation 
A one-way ANOVA revealed a main effect of acute CXCL12 exposure combined 
with the CaMKII inhibitor SC3039 and glutamate + glycine on synaptic CaMKII, F (5, 101) 
= 5.47, p < .001. REGW-Q revealed that acute CXCL12 exposure and visualization 15 min 
post- glutamate + glycine had significantly increased PSD/CaMKII ratios compared to ECS, 
while the 60 min conditions did not (Figure 9a).  
A one-way ANOVA revealed a main effect of sustained CXCL12 + SC3039 exposure 
and glutamate + glycine on cell death F (5, 96) = 4.73, p = .001. REGW-Q revealed that 
sustained CXCL12 + SC3039 exposure and visualization 15 min post- glutamate + glycine 
had significantly increased PSD/CaMKII ratios compared to ECS, while the 60 min 





Figure 9. CXCL12 + SC3039 PSD/CaMKII synaptic ratios. * indicates significant difference 
from ECS; # indicates significant difference from CXCL12;  p < .05. REGW-Q was used for 






















































































Sustained CXCL12 + SC3039 
*  
*  *  




Chapter 4: Discussion 
 
 
 Acute CXCL12 exposure and the corresponding activation of CXCR4 was not 
harmful to cells, as indicated by uptake of cell viability dye, while sustained exposure 
resulted in cell death rate of approximately 25% (Figure 4a). These results agree with 
previous observations of cell death rates following CXCL12 exposure of different time 
durations (Shepherd et al., 2012). Additionally, both acute and sustained CXCL12 exposure 
induced synaptic translocation of CaMKII, suggesting CXCL12 induced a rise of 
intracellular calcium sufficient enough to induce CaMKII translocation (Figure 7a). 
When cells were exposed to an excitotoxic stimulus (500µM glutamate + 10µM 
glycine) following acute CXCL12 exposure, cell death rates rose significantly (Figure 4a). 
When cells were exposed to a lower, physiologically relevant glutamate stimulus (100µM 
glutamate + 10µM glycine), cell death rates were similar to those seen following the high 
concentration excitotoxic stimulus (Figure 4a). Cell death was not observed following a brief 
sub-maximal glutamate stimulus without CXCL12 pre-exposure (100µM glutamate + 10µM 
glycine; Figure 3), suggesting that CXCL12 exposure may interfere with the cells ability to 
buffer against a large calcium influx that results from glutamate + glycine activation of 
NMDA receptors.  Interestingly, following the glutamate + glycine exposure, rates of cell 
death seemed to plateau by 15 minutes, as neurons examined for cell death at 60 minutes did 
not show marked increases above the 15 minute levels (Figure 3).  This may suggest the cell 
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death caused by this mechanism occurs rapidly in those cells that die, while cells that 
survived were still able to buffer against the calcium spike (Ankarcrona et al., 1995).  
When cells were challenged with glutamate + glycine following sustained CXCL12 
exposure, cell death rates were again higher than expected from both excitotoxic and 
physiologically relevant concentrations (Figure 4b). However, cell death rates did not plateau 
after 15 minutes as they did following the acute condition, instead the cell death rate was 
increased at 60 minutes, suggesting that the brief stimulus may activate slower apoptotic cell 
death mechanisms. Nicolai et al. (2010) previously demonstrated that prolonged CXCL12 
exposure downregulates NMDA receptors and is neuroprotective when cells were 
subsequently challenged to a sustained 100 µM NMDA stimulus 24 hours later. However, 
Nicolai et al. were investigating the role of a lower, more physiologically typical level of 
CXCL12 exposure (20nM CXCL12 compared to 100nM CXCL12 used here) that could be 
expected in non-ischemic conditions. In this case, CXCL12 down regulates NMDAR gene 
expression, and in order to see protective effects due to decreased NMDARs, the NMDA 
stimulus was not administered until 24 hours following initial CXCL12 exposure (Nicolai et 
al., 2010). It is possible that the CXCL12 paradigm used in the current study also enhances 
NMDAR downregulation, however it may not occur early enough to protect from a large 
glutamate challenge within 3 hours.   
The CaMKII-derived peptide inhibitor of CaM, SC3037, was able to completely 
inhibit synaptic translocation of CaMKII following both acute and sustained CXCL12 
exposure, as well as following a subsequent application of glutamate (Figure 8).  This 
corresponded to inhibition of cell death following acute CXCL12 exposure and the lower, 
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physiologically relevant glutamate stimulus (Figure 5a). However, the rate of cell death 
observed 60 minutes after the application of the excitotoxic stimulus (500µM) was greater 
than CXCR4 activation alone (p < .05). This suggests that inhibition of CaM decreases the 
CXCL12-induced enhancement of glutamate-induced cell death; however, CaM acts on a 
multitude of substrates and the inhibition of CaMKII translocation is likely only one of the 
many effects that CaM inhibition induced.   
Inhibition of CaM during sustained CXCL12 exposure did not completely inhibit 
CXCL12-induced cell death, although it appears to be partially attenuated compared to 
CXCL12 exposure alone (Figure 5b). This is in agreement with Shepherd et al. (2012), who 
saw a significant reduction in cell death (but not a return to baseline) through the inhibition 
of calcineurin, a Ca
2+
/CaM dependent phosphatase (Figure 2). It may be that the slight 
reduction in cell death seen here was due to a reduction in calcineurin activity. Additionally, 
inhibition of CaM reduced cell death observed following additional glutamate stimulus. 
Together, these data suggest that inhibition of CaM is not sufficient to completely inhibit 
CXCL12-induced cell death, although it does protect from cell death induced by subsequent 
glutamate signaling.  
The inhibition of CaMKII catalytic activity with the CaMKII-derived peptide 
inhibitor of CaMKII, SC3039 greatly reduced the rate of cell death following acute CXCL12 
exposure and the subsequent glutamate + glycine challenge, suggesting that the inhibition of 
CaMKII activity protects from this particular excitotoxic stimulus (Figure 6). 
SC3039 did not inhibit translocation of CaMKII to the synapse (Figure 9). This was 
expected because of the nature in which SC3039 inhibits CaMKII. SC3039 binds to the s-site 
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and a portion of the t-site of the Ca
2+
/CaM bound CaMKII, inhibiting the ability for ATP 
binding and subsequent autophosphorylation and autonomy of CaMKII (Bayer et al., 2001; 
Appendix D). When acute CXCL12 + SC3039 incubated cells were subsequently treated to 
toxic (500µM) and sub-toxic (100µM) glutamate levels, CaMKII synaptic translocation 
persisted and was still present at 15 minutes post-treatment. Interestingly, when visualized 60 
minutes post glutamate + glycine application, CaMKII synaptic translocation no longer 
significantly elevated compared to CXCL12 alone. This may have been due to a weak 
CaMKII interaction with the GluN2B tail, which would allow CaMKII to dissociate and 
return to the dendrite (Bayer et al., 2006).  Another possible explanation is that SC3039 was 
degraded by proteolysis during the 60 minute incubation (Otmakov et al., 1997) which 
subsequently allowed ATP binding and burst T305/306 phosphorylation in the absence of 
Ca
2+
/CaM. Burst phosphorylation shuts down CaMKII and induces a return of synaptic 
CaMKII to baseline (Strack, 1997).  In either case, it seems CaMKII synaptic translocation 
alone is not necessary for CXCL12 enhancement of glutamate + glycine induced cell death. 
The pattern of CaMKII synaptic translocation following sustained CXCL12 + 
SC3039 exposure followed a similar pattern of translocation as the acute condition. Again, 
synaptic accumulation of CaMKII occurred following CXCL12 + SC3039 and glutamate 
exposure; however, cell death was notably attenuated compared to CXCL12 + glutamate 
exposure without the CaMKII inhibitor, as well as excitotoxic 500µM glutamate + glycine 
exposure without CXCL12 exposure (Figure 3). This further supports that inhibition of 
CaMKII preferentially inhibits glutamate induced cell death following a prolonged exposure 
to CXCL12.  
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The role of CaMKII in post-CXCL12 ischemic cell death may help explain why 
simple glutamate blocking drugs do not always reduce cell death following ischemic attacks 
(Lau & Tymianski, 2010). Glutamate antagonists are typically only partial antagonists, 
however the data here suggest that even low glutamate activity can cause cell death following 
high CXCL12 exposure that may be present following global ischemia. Indeed, work with 
potent CaMKII-specific inhibitors, with stronger affinity and better specificity (Vest et al., 
2007) than the peptides used here, have been able to significantly reduce glutamate-induced 
cell death, even when administered after a glutamate insult (Vest et al., 2010; Ashpole et al., 
2011).  
More recently, McCord et al. (2013) demonstrated that CaMKII inhibition greatly 
reduces activated microglial (AMG) induced cell death. McCord et al. proposed that this cell 
death is occurs via a mechanism similar to CXCL12 activated cell death proposed by 
Shepherd et al. (2012); i.e., AMG activates CaMKII through intracellular calcium release, 
and subsequently CaMKII facilitates insertion of Kv2.1 channels which promote excessive 
potassium efflux. It is unclear if the current experiment also inhibited Kv2.1 insertion using 
peptide inhibitors, however it is likely one of the processes that was inhibited as CaMKII 
phosphorylation of syntaxin is required for Kv2.1 insertion and the detrimental enhancement 
of potassium efflux (McCord et al., 2013). In addition, although CaMKII inhibition appeared 
to reduce cell death following sustained CXCL12 exposure compared to non-inhibited 
conditions, it was not completely attenuated, suggesting CaMKII phosphorylation is 
necessary for CXCL12 induced cell death, but not sufficient.  Thus, other molecular 
mechanisms are likely triggered by CXCL12 exposure/CXCR4 activation which contribute 
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to cell death, but inhibition of CaMKII at least partially protects from some of the negative 
effects of excitotoxicity.  
Several types of CaMKII mutants exist which can help distinguish the substrate 
interactions necessary for CXCL12/glutamate + glycine induced cell death. For example, 
CaMKII-I205K specifically inhibits GluN2B interaction, but leaves kinase activity intact 
(Bayer et al., 2006). This would highlight if the GluN2B interaction is necessary. 
Additionally, CaMKII-T286A impairs autonomy but leaves kinase ability intact during the 
calcium stimulus (Coultrap et al., 2012); this would demonstrate if CXCL12 cell death can be 
initiated by brief activity of CaMKII. Through these experiments, it may be possible to 
resolve any specific interactions are required for CXCL12 induced cell death.  
Taken together, the current study supports further investigation of CaMKII as a 
potential therapeutic target to decrease cell death following global ischemia. Because 
CaMKII can act on such a multitude of substrates in the synapse and is important for many 
normal functions, including learning and memory, determining how to inhibit only the 
specific interaction involved in excitotoxicity-related cell death may be key to utilizing 
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Figure A1. Left: ECS exposed neuron images of CaMKII (red; top), PSD95 (green; middle) 
and Overlay (multi; bottom). CaMKII appears very diffuse without stimulation of cells. 
Overlay shows that CaMKII is not colocalized to the synaptic marker protein, PSD95. Right: 
Acute CXCL12 exposed neuron images of CaMKII (red; top), PSD95 (green; middle) and 
Overlay (multi; bottom). CaMKII appears punctate. Overlay shows that CaMKII puncta are 








Figure B1. Sample immunohistochemistry neurons. Top: Overlay image of ECS images at 
20X includes DIC image with DAPI channel and CY5 channel. Blue indicates all cells, red 






Figure C1. Schematic depicting the order in which CXCL12 and glutamate + glycine are 
applied. CXCL12 is applied, followed by glutamate + glycine. Cells are then fixed after 15 or 
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Figure D1. CaMKII regulatory domain is typically autoinhibited by the autoinhibitory 
domain (blue). When the autoinhibitory domain is bound by Ca/CaM, the t-site and the s-site 
become exposed. This allows for ATP to bind as well as phosphorylation of T286, both of 
which can leave the kinase active following the dissociation of CaM (top left). In addition, 
GluN2B can bind to the t-site of CaMKII to keep the kinase locked in an open position in the 
absence of CaM (top right). In the presence of SC3039, the t-site only remains partially 
available for GluN2B interaction, it is unclear if SC3039 allows any GluN2B interaction. 
However, SC3039 (orange) occupies the ATP binding domain and the kinase is not 
catalytically active (bottom right). In the presence of SC3037, Ca
2+
/CaM binds SC3037 when 
activated; if Ca
2+
/CaM binds CaMKII, SC3037 can bind CaMKII and inhibit ATP binding. 
Figure based on data from Bayer et al. (2001; 2006) and Rosenberg et al. (2005).  
